Navigation Links
New test to study proteins involved in neurodegenerative diseases
Date:2/2/2011

Researchers from the Institute of Biotechnology and Biomedicine and the UAB Department of Biochemistry and Molecular Biology have developed and patented a method using Saccharomyces cerevisiae yeast to detect in human proteins the formation of oligomers, small toxic aggregations of molecules which can initiate the assembly of amyloid fibres found in neurodegenerative diseases. The test allows validating the efficacy of compounds which could dissolve or inhibit these aggregates, as well as studying at basic level the therapeutic potentiality of a large number of molecules.

Oligomers are formed by the union of two to twenty molecules. Recent research studies seem to indicate that their toxicity is higher than that of amyloid fibres. However, studying these substances is not easy given that they are unstable and their formations are transitory.

The method developed by researchers at UAB locates and monitors in vivo the aggregation process of the protein using fluorescence techniques and without the need to resort to alternative methods. It also allows studying compounds which inhibit oligomers as potentially therapeutic mechanisms to prevent posterior formations of amyloid plaques.

The screening system was carried out by genetically modifying Saccharomyces cerevisiae yeast to link human protein aggregation to cell death. It is based on the fusion of the human peptide under study with the human variant of a protein needed for the survival of the modified yeast, dihydrofolate reductase (DHFR). The aggregation of the peptide deactivates the DHFR protein and finally produces the death of the cell, thereby providing a detection system of molecules with tendency to aggregate and in which any compound capable of separating or inhibiting this aggregation would favour the survival of the cell.

Researchers carried out the study with the AB42 peptide, the main cause of Alzheimer's disease. To validate the test they worked with several compounds in vitro which, in studies related to the disease, had demonstrated to be effective against the formation of oligomers, amyloid fibres or both types of molecules. The system only showed to be effective with compounds affecting oligomers, which makes it a very specific method for the initial detection of the aggregation process. The system was also validated with chaperones, a group of proteins which increase the dissolution of protein aggregation and favour cell survival. In addition to AB42, researchers validated the assay with regard to the detection of initial aggregations, by using proteins involved in Parkinson's and Huntington's disease.

According to Salvador Ventura, one of the authors of the study, the system is easy to use and allows scientists to work quickly and to analyse with reliability the potential therapeutic efficacy of an infinite number of compounds at experimental level. Now there is the need to automate the system - with plates allowing for the simultaneous analysis of more than fifty molecules per assay - to be used in basic research. For the moment the system has been patented by the researchers.


'/>"/>

Contact: Maria Jesus Delgado
MariaJesus.Delgado@uab.cat
34-935-814-049
Universitat Autonoma de Barcelona
Source:Eurekalert

Related biology technology :

1. A new model for studying Parkinsons
2. Cephalon Announces Positive Topline Results From a Phase IV Study of NUVIGIL in Shift Work Disorder
3. Columbia University researchers use nanoscale transistors to study single-molecule interactions
4. New Clinical Study Finds Masimo Noninvasive Hemoglobin Accurate in Patients with Critically Low Hemoglobin Levels
5. New Johns Hopkins School of Medicine Study Shows Masimo Noninvasive Hemoglobin Monitoring is Accurate During Complex Spine Surgeries
6. Professor Dennis Lo Trisomy 21 Clinical Validation Study Published in British Medical Journal
7. Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy
8. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
9. Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans
10. NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate
11. Sequenom Announces Publication Acceptance of Manuscript From Trisomy 21 R&D Verification Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... ... April 20, 2017 , ... As ... webinar will explore challenging patient cases when screening for direct oral anticoagulant. When ... be a need for bridging parental anticoagulation especially for those at high risk ...
(Date:4/20/2017)... ... April 20, 2017 , ... NetDimensions appoints Bill Mastin, a learning technology ... years of experience in the learning technologies industry, Mastin joins NetDimensions from the New ... Group plc (LTG). At LEO, Mastin served as SVP of the North America offices ...
(Date:4/20/2017)... Dutch philosopher Koert van Mensvoort - founder of the Next Nature ... Eindhoven - has written a ,Letter to Humanity, in support of ... becoming a slave and victim to its own technology, but to employ technology ... ... Mensvoort – founder of the Next Nature Network and Fellow of ‘Next Nature’ ...
(Date:4/19/2017)... ... April 18, 2017 , ... Alisa Wright, founder and CEO of Singota ... College of Pharmacy in Lafayette, Indiana. , The Distinguished Alumni Award was established ... careers and other scientific endeavors. , Wright began her career in the pharmaceutical ...
Breaking Biology Technology:
(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...
(Date:4/11/2017)... April 11, 2017 No two people ... at the New York University Tandon School of ... have found that partial similarities between prints are ... in mobile phones and other electronic devices can ... The vulnerability lies in the fact that fingerprint-based ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
Breaking Biology News(10 mins):